Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410453 | 1.00 | QPCT (0.83) | QPCTQPCTL | |
| SCHEMBL466547 | 0.83 | QPCT (0.82) | QPCTQPCTL | |
| SCHEMBL29410584 | 0.83 | QPCT (0.82) | QPCTQPCTL | |
| SCHEMBL466464 | 0.81 | QPCT (0.83) | QPCTQPCTL | |
| SCHEMBL29410464 | 0.81 | QPCT (0.84) | QPCTQPCTL | |
| SCHEMBL466478 | 0.81 | QPCT (0.84) | QPCTQPCTL | |
| SCHEMBL29410545 | 0.80 | QPCT (0.83) | QPCTQPCTL | |
| SCHEMBL466449 | 0.80 | QPCT (0.83) | QPCTQPCTL | |
| SCHEMBL1444364 | 0.79 | QPCT (0.55) | QPCTQPCTL | |
| SCHEMBL29410563 | 0.79 | QPCT (0.55) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | claimed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | claimed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | claimed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | claimed |
| EP-2344157-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | claimed |
| EP-2344158-A1 | Use of isoQC inhibitors | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | claimed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | claimed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | claimed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | disclosed |
| EP-3747438-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747437-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | QPCT 4/4885QPCTL 43/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | QPCT 1/4885QPCTL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.